(Q34555328)

3 August 2017

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome (English)

1 reference

3 August 2017

neuromuscular junction

1 reference

T J Lehky

1

1 reference

3 August 2017

F M Iwamoto

2

1 reference

3 August 2017

T N Kreisl

3

1 reference

3 August 2017

M K Floeter

4

1 reference

3 August 2017

H A Fine

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

3 August 2017

1 reference

3 August 2017

76

1 reference

3 August 2017

3

1 reference

3 August 2017

236-241

1 reference

In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

FLT3 kinase inhibitors in the management of acute myeloid leukemia.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034397

Drug-induced autoimmune myasthenia gravis

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21242491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Strong immunoreactivity of platelet-derived growth factor and its receptor at human and mouse neuromuscular junctions

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21242491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0B013E3182074A69

1 reference

3 August 2017

1 reference

3 August 2017

1 reference